Inflarx N.V. (IFRX)
NASDAQ:IFRX
Want to see IFRX full AI Analyst Report?
IFRX Stock Chart & Stats
$1.59
-$0.16(-6.27%)
At close: 4:00 PM EST
$1.59
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.74 - $2.95
Previous CloseN/A
Volume66.97K
Average Volume (3M)1.91M
Market Cap
$266.60M
Enterprise Value$99.94M
Total Cash (Recent Filing)$39.84M
Total Debt (Recent Filing)$823.88K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 06, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding147,292,860
10 Day Avg. Volume1,277,127
30 Day Avg. Volume1,914,256
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)1972.04
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue3.41K
Enterprise Value/Gross Profit-13.82
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$8.00Price Target Upside403.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$15.50K
Bulls Say, Bears Say
Bulls Say
Capital Raising / RunwayThe $150M underwritten equity raise materially strengthens InflaRx's near- to medium-term funding capacity. This durable capital buffer supports planned izicopan development and Phase 2 proof-of-concept work, reducing near-term financing risk and enabling execution of clinical milestones over the next 2–3 years.
Focused Pipeline StrategyConcentrating resources on izicopan for ANCA-associated vasculitis and other renal complement diseases tightens development priorities. This strategic focus increases chances of meaningful clinical readouts, improves resource allocation, and creates clearer regulatory and partnership pathways across high-unmet-need indications.
Favorable Preclinical Safety/DDI ProfileIzicopan's low reactive metabolite signal and prior tolerability data, together with no CYP3A4 time-dependent inhibition, reduce development and chronic-use risk. Durable safety and low drug–drug interaction potential enhance appeal for combination regimens, chronic indications, and future partnering or label expansion.
Bears Say
Persistent Operating LossesOperating performance remains loss-making with negligible revenue and deeply negative gross profit, reflecting a business still pre-commercial. Persistent losses indicate ongoing reliance on external financing and mean management must deliver clinical progress to justify continued capital support and avoid value erosion.
Sustained Cash BurnMaterial negative operating and free cash flow show that reported losses translate into real cash outflows. Even with recent improvement, the sustained burn creates a structural need for financing to fund trials, compressing flexibility and making execution sensitive to capital markets and milestone timing.
Dependence On Equity Financing / Dilution RiskBoard-authorized share issuance powers, an expanded capital base and a recent large $150M offering signal structural dependence on equity to fund operations. While necessary now, recurring equity raises increase dilution risk for existing holders and can pressure per-share economics absent material clinical or commercial derisking.
InflaRx News
IFRX FAQ
What was Inflarx N.V.’s price range in the past 12 months?
Inflarx N.V. lowest stock price was $0.74 and its highest was $2.95 in the past 12 months.
What is Inflarx N.V.’s market cap?
Inflarx N.V.’s market cap is $266.60M.
When is Inflarx N.V.’s upcoming earnings report date?
Inflarx N.V.’s upcoming earnings report date is Aug 06, 2026 which is in 45 days.
How were Inflarx N.V.’s earnings last quarter?
Inflarx N.V. released its earnings results on May 07, 2026. The company reported -$0.092 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.044.
Is Inflarx N.V. overvalued?
According to Wall Street analysts Inflarx N.V.’s price is currently Undervalued.
Does Inflarx N.V. pay dividends?
Inflarx N.V. does not currently pay dividends.
What is Inflarx N.V.’s EPS estimate?
Inflarx N.V.’s EPS estimate is -0.07.
How many shares outstanding does Inflarx N.V. have?
Inflarx N.V. has 147,292,860 shares outstanding.
What happened to Inflarx N.V.’s price movement after its last earnings report?
Inflarx N.V. reported an EPS of -$0.092 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Inflarx N.V.?
Currently, no hedge funds are holding shares in IFRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InflaRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (403.14% Upside)
$8.00 (403.14% Upside)
Blogger Sentiment
Bullish
IFRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 13.0%
Last 30 Days ▼ 13.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.81%
12-Months-Change
Fundamentals
Return on Equity
-94.90%
Trailing 12-Months
Asset Growth
-40.06%
Trailing 12-Months
Company Description
Inflarx N.V.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
IFRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(403.14% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
9.30% Other Institutional Investors
90.67% Public Companies and
Individual Investors